ED, LDN & specialty formulations · Wichita, Kansas
Low-dose naltrexone (LDN) in Wichita
Low-dose naltrexone (LDN) capsules, titration strengths and filler-free options. Prepared through Hart Pharmacy & Home Medical Equipment with a valid prescription and clinical review.
Availability & preparation
Hart offers low-dose naltrexone (ldn) as part of our ed, ldn & specialty formulations services. Each preparation is reviewed for the individual prescription and applicable regulations. Offered does not mean immediately in stock.
Call 316-683-5621 to confirm the prescribed ingredients, strength, dosage form, pricing and preparation time. Our pharmacy can also review transfer eligibility with your current pharmacy and prescriber.
Dosing & administration
Your prescriber selects the LDN capsule strength, starting dose and any titration. Low-dose does not describe one standard dose. Follow your prescription label, and discuss opioid use and other medicines with your clinician before starting or changing the preparation.
There is no single dose for every patient. The amount, concentration, frequency and any changes must follow your prescription and clinician’s instructions. This page does not provide an individual dosing recommendation.
Discuss with your pharmacist
- Confirm the exact ingredients, strength and prescribed dosage form.
- Review the clinician's starting-dose and titration instructions.
- Ask about administration training, interactions and when to seek medical help.
For a private discussion of your prescription or medical history, call our pharmacy. Do not send patient health information through the website contact form.
Your local Wichita compounding pharmacy
Visit Hart’s public pharmacy at 6217 E 13th St N, Wichita, KS 67208 for prescription questions and pickup. Ask about free once weekly local prescription delivery or Kansas shipping options; arrangements are confirmed for your prescription.
Compounded medications are not FDA-approved and are not automatically equivalent to an approved medicine or another pharmacy’s preparation. A change of formulation requires clinical review. Other peptides are coming soon, not currently offered.
